Drug Profile
DRGT 18 2
Alternative Names: DRGT-18-2Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Druggability Technologies
- Developer Tavanta Therapeutics
- Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
- Mechanism of Action Immunosuppressants; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Renal cell carcinoma
Most Recent Events
- 07 Dec 2022 Discontinued - Phase-I for Renal cell carcinoma (PO)
- 07 Dec 2022 Discontinued - Phase-II for Cancer (PO)
- 01 Sep 2020 Druggability Technologies is now called Tavanta Therapeutics